VivoSeq
Cardiovascular

Coronary Atherosclerosis

34

Pipeline Programs↗

4

Active Trials↗

16

Companies Involved↗

Coronary Atherosclerosis is a moderately active landscape with 34 programs across 16 companies. The most active players are Amgen, Viatris Specialty LLC, Chong Kun Dang Pharmaceutical. 19 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

6/100

Mech. Concentration

19/100

Completion Rate

69/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 3Sanofi logo

Sanofi

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

ApprovedTakeda logo

Takeda

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

35 of 37 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody13%Peptide13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed11 · 41%
Unknown status7 · 26%
Recruiting4 · 15%
Withdrawn3 · 11%
Terminated2 · 7%

Clinical Trials

Trial Activity

27 trials

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
Recruiting·—·N/A·NCT03504956·150 enrolled
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Recruiting·—·Phase 4·NCT05708859·120 enrolled
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
Recruiting·MMassachusetts General Hospital·Phase 4·NCT05850091·200 enrolled
YN001-004 in Patients With Coronary Atherosclerosis in Australia
Recruiting·BBeijing Inno Medicine Co., Ltd.·Phase 2·NCT06700720·24 enrolled
Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Completed·—·N/A·NCT05708547·61 enrolled
Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis
Completed·MMayo Clinic·Phase 1·NCT03471611·21 enrolled
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Completed·GGuerbet·Phase 4·NCT01254552·351 enrolled
Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02926027·80 enrolled
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Completed·JJohns Hopkins University·Phase 2·NCT02624180·81 enrolled
Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial
Completed·LLaval University·Phase 3·NCT00169832·193 enrolled
Effect of Evolocumab on Coronary Atherosclerosis
Completed·—·Phase 3·NCT03689946·55 enrolled
DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy
Completed·TThe Catholic University of Korea·N/A·NCT04825795·4,007 enrolled
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans
Completed·MMayo Clinic·Phase 3·NCT01067339·70 enrolled
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT06342609·84 enrolled
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
Completed·BBeijing Inno Medicine Co., Ltd.·Phase 1/2·NCT06048588·144 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)